doctoral thesis
Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma

University of Split
School of Medicine

Cite this document

Göbel, H. (2023). Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma (Doctoral thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:883713

Göbel, Holger. "Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma." Doctoral thesis, University of Split, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:171:883713

Göbel, Holger. "Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma." Doctoral thesis, University of Split, School of Medicine, 2023. https://urn.nsk.hr/urn:nbn:hr:171:883713

Göbel, H. (2023). 'Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma', Doctoral thesis, University of Split, School of Medicine, accessed 14 November 2024, https://urn.nsk.hr/urn:nbn:hr:171:883713

Göbel H. Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma [Doctoral thesis]. Split: University of Split, School of Medicine; 2023 [cited 2024 November 14] Available at: https://urn.nsk.hr/urn:nbn:hr:171:883713

H. Göbel, "Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radio chemotherapy of esophageal adenocarcinoma", Doctoral thesis, University of Split, School of Medicine, Split, 2023. Available at: https://urn.nsk.hr/urn:nbn:hr:171:883713

Please login to the repository to save this object to your list.